(Nasdaq: TNFA) Holds Strong Early Tuesday On A Solid Green Surge (Could A Reversal Be Underway?)

TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) continues to hold on to its early green move Tuesday.

*Sponsored StockWireNews (Nasdaq: TNFA) Holds Strong Early Tuesday On A Solid Green Surge (Could A Reversal Be Underway?) February 18th Greetings Readers, TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) continues to hold on to its early green move Tuesday. This could be extremely significant... At the end of last week, some of TNFA's technical indicators suggested it to be in oversold territory. And even after a strong green start today, TNFA's 9-Day and 14-Day Relative Strength Indices are both below 40%. If this is a reversal/bounce situation, it's critical to note the size of this Nasdaq profile's float. Tallying roughly 2.39Mn shares in its float, volatility potential could be explosive on a daily basis. (Nasdaq: TNFA) continues to hold my watchlist's top spot. Read the report below and consider this profile for your radar quickly. ----- *TNF Pharmaceuticals, Inc. (Nasdaq: TNFA)* TNF Pharmaceuticals, Inc. (Nasdaq: TNFA), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. And based on several potential catalysts, TNFA could be due for some serious breakout buzz. Check them out: No. 1 - Could A Really Low Float Create A Volatile Environment? No. 2 - Positive Clinical Data Milestone Supports Expanding Studies (Successfully Completed An FDA-Recommended Study). No. 3 - Key Study Series Launched (The Ball Starts Rolling). No. 4 - Oversold Leaning Technicals Suggest Healthy Reversal/Bounce Potential Could Be Significant! No. 5 - A Recent In-vest-ment Screams Confidence In TNFA's MYMD-1 Potential. But more on those in a second... Company Breakdown - What Makes TNF Pharmaceuticals, Inc. Special As a clinical stage biopharma company, TNF Pharmaceuticals is developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory diseases. Their lead clinical candidate, MYMD-1® is an orally available, next-generation TNF-alpha inhibitor with the potential to transform the way TNF-alpha based diseases are treated. With its small molecule design, selective mechanism of action, and ability to cross the blood brain barrier, MYMD-1® has the potential to disrupt the TNF-alpha inhibitor market and provide meaningful therapeutic solutions to patients not served by current therapies. MYMD-1® has demonstrated the potential to slow the aging process and extend healthy lifespan. The product is being evaluated in Phase 2 studies for sarcopenia/frailty, a result of the aging process, as well as early-stage trials for rheumatoid arthritis (RA), with the potential to expand into other applications. A second therapeutic candidate, Supera-C-B-D, is a novel, synthetic, non-toxic cann-a-bidiol (C-B-D) analog that is 8,000 times more potent as a C-B-2 agonist (activator) than plant-based C-B-D. In addition to its potential role in managing anxiety, chronic pain and seizures, Supera-C-B-D has been shown to have anti-inflammatory effects. ----- TNF Pharmaceuticals, Inc. Pipeline

Sources: TNFA Website. ----- As mentioned above, (Nasdaq: TNFA) has several potential catalysts to consider starting right now. Take a look: No. 1 TNFA Potential Catalyst - Could A Really Low Float Create A Volatile Environment? According to info from the Yahoo Finance website, TNFA has a low float. The website reports this profile to have roughly 2.39Mn shares in its float. Why is that important? It's important on one crucial level. Volatility potential. Could positive company news early in 2025 provide a breakout spark? ----- No. 2 TNFA Potential Catalyst - Positive Clinical Data Milestone Supports Expanding Studies (Successfully Completed An FDA-Recommended Study). TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion Set to begin larger Phase 2b study in sarcopenia and new trial in GLP-1-induced sarcopenia and frailty Transformative potential for novel TNF-alpha inhibitor drug:Estimated $4Bn TNF inhibitor market and $50Bn GLP-1 agonist market BALTIMORE, January 15, 2025--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNFA" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel oral therapies for autoimmune and inflammatory conditions, today announced that it has achieved a key safety data milestone supporting expanded and longer-term clinical studies of its novel TNF-alpha (TNF-α) inhibitor drug, isomyosamine, in multiple indications. The Company successfully completed an FDA-recommended study of isomyosamine that demonstrated clinical safety throughout 13 weeks of treatment at all dose levels evaluated. "Positive data from this milestone study confirms isomyosamine's historically strong safety profile and enables us to extend the duration of future clinical trials," said Mitchell Glass, M.D., President and Chief Medical Officer of TNFA. "We believe we are fully equipped to advance our comprehensive isomyosamine platform in a longer-term clinical trial in sarcopenia and future studies in multiple conditions associated with immunometabolic dysregulation." ... Read the full article here. ----- No. 3 TNFA Potential Catalyst - Key Study Series Launched (The Ball Starts Rolling). TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Wei-ght Lo-ss Treatment Series of studies to observe signals of inflammation and TNF-alpha levels in patients taking GLP-1s including We-govy® or O-zempic® Lean body mass accounts for up to 40% of wei-ght lo-ss from GLP-1 treatments Potential entry into high growth GLP-1 market of nearly $50Bn in 2024, projected value of $100Bn by 2029 BALTIMORE, January 29, 2025--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that it has initiated the first in a series of studies to evaluate the impact of its novel oral TNF-alpha (TNF-α) inhibitor drug, isomyosamine, in preserving lean muscle mass during and after GLP-1 treatment for wei-ght lo-ss and chronic weight management. ... Read the full article here. ----- No. 4 TNFA Potential Catalyst - Oversold Leaning Technicals Suggest Healthy Reversal/Bounce Potential Could Be Significant! At 4:00PM EST Friday, Barchart was reporting multiple oversold leaning technical indicators for TNFA. These technicals could be signaling a healthy reversal is approaching in the near term. Here's the definition of a "reversal" from Investopedia: "A reversal is a change in the price direction of an asset. A reversal can occur to the upside or downside. Following an uptrend, a reversal would be to the downside. Following a downtrend, a reversal would be to the upside. Reversals are based on overall price direction and are not typically based on one or two periods/bars on a chart." Here's the technicals to pay close attention to (as of 4:00PM EST Friday): 9-Day Relative Strength Index: 27.69% 14-Day Relative Strength Index: 31.46% When these numbers drop down to the 30% range and lower, they can be viewed as being in oversold territory. While in this territory, they can paint the picture of a profile that is undervalued. 14-Day Raw Stochastic: 8.12% 14-Day Williams %R: 91.88% As the Raw Stochastic nears the 10% range and lower and the Williams %R nears the 90% range or higher, these technical indicators may also be viewed as oversold and undervalued. Keep an eye on these technicals closely. ----- No. 5 TNFA Potential Catalyst - A Recent In-vest-ment Screams Confidence In TNFA's MYMD-1 Potential. TNF Pharmaceuticals Announces Strategic Equity In-vest-ment Priced at a Premium to Market Prevail Partners, LLC in-vest-ment priced at more than a 40% premium to market Prevail InfoWorks, Inc. to act as Clinical Research Organization partner; global full service CRO with hundreds of clinical trials over a decade TNF Pharmaceuticals fully funded for clinical trials for next two years BALTIMORE, October 02, 2024--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNFA" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel oral therapies for autoimmune and inflammatory conditions, today announced that it has secured a strategic equity in-vest-ment, priced at a 20% premium to a 30-trading days volume weighted average price (VWAP), from Prevail Partners, LLC, a U.S. in-vest-ment fund focused on life sciences companies. The Company has engaged global full-service Clinical Research Organization (CRO) Prevail InfoWorks, Inc., an affiliate of Prevail Partners, to provide clinical services for the next Phase 2 clinical study using our proprietary drug in sarcopenia/frailty. ... Read the full article here. ----- (Nasdaq: TNFA) Recap - 5 Potential Catalysts That Could Generate Buzz No. 1 - Could A Really Low Float Create A Volatile Environment? No. 2 - Positive Clinical Data Milestone Supports Expanding Studies (Successfully Completed An FDA-Recommended Study). No. 3 - Key Study Series Launched (The Ball Starts Rolling). No. 4 - Oversold Leaning Technicals Suggest Healthy Reversal/Bounce Potential Could Be Significant! No. 5 - A Recent In-vest-ment Screams Confidence In TNFA's MYMD-1 Potential. ----- Coverage is officially initiated on TNF Pharmaceuticals, Inc. (Nasdaq: TNFA). If updates pop up, I'll get them out quickly. Talk soon. Sincerely, Kai Parker StockWireNews (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)

*StockWireNews (stockwirenews . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and StockWireNews ("SWN") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 02/17/25 and ending on 02/18/25 to publicly disseminate information about (TNFA:US) via digital communications. Under this agreement, SWN Media LLC was paid seventeen thousand USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the funds from the issuer and does not own st-ock in the issuer but the reader should assume that the clients of the third party own shares in the issuer that they will liquidate at or near the time you receive this communication, which has the potential to hurt share prices. Neither SWN Media LLC or its member own shares of (TNFA:US). Please see important disclosure information here: https://stockwirenews.com/disclosure/tnfa/#details Unsubscribe Stock Wire News 160 West Camino Real Unit 886 Boca Raton, Florida 33432 United States